SRPK1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08769(SRPK1 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08769(SRPK1 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

SRPK1 (Serine-Arginine Protein Kinase 1) is a key enzyme involved in regulating pre-mRNA splicing by phosphorylating serine-arginine (SR) repeat domains in splicing factors. This phosphorylation modulates the subcellular localization and activity of SR proteins, influencing spliceosome assembly and alternative splicing decisions. SRPK1 dysregulation has been implicated in various diseases, including cancer, viral infections, and neurological disorders. In cancer, SRPK1 overexpression promotes angiogenesis, metastasis, and chemoresistance by altering splicing of oncogenic transcripts like VEGF. It also interacts with viral proteins to facilitate replication in certain infections.

SRPK1 antibodies are essential tools for studying its expression, localization, and function. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use these antibodies to explore SRPK1's role in disease mechanisms and assess its potential as a therapeutic target. Small-molecule inhibitors of SRPK1 are under investigation for cancer therapy, emphasizing the need for reliable antibodies to validate target engagement and downstream effects. Specific SRPK1 antibodies also help distinguish it from related kinases (e.g., SRPK2) in functional studies. As aberrant splicing emerges as a hallmark of many diseases, SRPK1 remains a focal point for understanding post-transcriptional gene regulation.